[go: up one dir, main page]

WO2006020114A3 - Regions fc de variants - Google Patents

Regions fc de variants Download PDF

Info

Publication number
WO2006020114A3
WO2006020114A3 PCT/US2005/025276 US2005025276W WO2006020114A3 WO 2006020114 A3 WO2006020114 A3 WO 2006020114A3 US 2005025276 W US2005025276 W US 2005025276W WO 2006020114 A3 WO2006020114 A3 WO 2006020114A3
Authority
WO
WIPO (PCT)
Prior art keywords
variant
regions
provides
altered
confer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/025276
Other languages
English (en)
Other versions
WO2006020114A2 (fr
Inventor
Barrett Allan
Weidong Jiang
Ying Tang
Jeffry Dean Watkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Molecular Evolution Inc
Original Assignee
Applied Molecular Evolution Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK05773014.5T priority Critical patent/DK1776384T3/da
Priority to PL05773014T priority patent/PL1776384T3/pl
Priority to CA2573192A priority patent/CA2573192C/fr
Priority to BR122018016031A priority patent/BR122018016031B8/pt
Priority to EP05773014.5A priority patent/EP1776384B1/fr
Priority to BRPI0514068A priority patent/BRPI0514068B8/pt
Priority to JP2007524825A priority patent/JP5055603B2/ja
Priority to ES05773014T priority patent/ES2426816T3/es
Priority to US11/572,634 priority patent/US7740847B2/en
Priority to EA200700210A priority patent/EA012464B1/ru
Priority to CA2779559A priority patent/CA2779559A1/fr
Priority to AU2005274905A priority patent/AU2005274905B2/en
Application filed by Applied Molecular Evolution Inc filed Critical Applied Molecular Evolution Inc
Priority to MX2007001345A priority patent/MX2007001345A/es
Priority to CN2005800261833A priority patent/CN101001873B/zh
Publication of WO2006020114A2 publication Critical patent/WO2006020114A2/fr
Publication of WO2006020114A3 publication Critical patent/WO2006020114A3/fr
Priority to IL180885A priority patent/IL180885A0/en
Anticipated expiration legal-status Critical
Priority to NO20071192A priority patent/NO339556B1/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention porte sur des polypeptides, notamment sur des anticorps thérapeutiques, comprenant une nouvelle région Fc de variant. L'invention porte également sur des régions Fc de variants conférant une fonction effectrice modifiée ou une demi-vie sérique modifiée sur un polypeptide auquel une région Fc du variant est liée de manière fonctionnelle.
PCT/US2005/025276 2004-08-04 2005-07-18 Regions fc de variants Ceased WO2006020114A2 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
CA2779559A CA2779559A1 (fr) 2004-08-04 2005-07-18 Regions fc de variants
CA2573192A CA2573192C (fr) 2004-08-04 2005-07-18 Regions fc de variants
BR122018016031A BR122018016031B8 (pt) 2004-08-04 2005-07-18 processo para produzir um anticorpo monoclonal variante com resposta de adcc realçada
EP05773014.5A EP1776384B1 (fr) 2004-08-04 2005-07-18 Regions fc de variants
BRPI0514068A BRPI0514068B8 (pt) 2004-08-04 2005-07-18 anticorpo anti-cd20, e, composição farmacêutica
JP2007524825A JP5055603B2 (ja) 2004-08-04 2005-07-18 変異Ｆｃ領域
ES05773014T ES2426816T3 (es) 2004-08-04 2005-07-18 Regiones Fc variantes
US11/572,634 US7740847B2 (en) 2004-08-04 2005-07-18 Variant Fc regions
EA200700210A EA012464B1 (ru) 2004-08-04 2005-07-18 Антитело против cd20 и его применение
DK05773014.5T DK1776384T3 (da) 2004-08-04 2005-07-18 VARIANT-Fc-REGIONER
PL05773014T PL1776384T3 (pl) 2004-08-04 2005-07-18 WARIANTY REGIONÓW Fc
AU2005274905A AU2005274905B2 (en) 2004-08-04 2005-07-18 Variant Fc regions
MX2007001345A MX2007001345A (es) 2004-08-04 2005-07-18 Regiones variantes fc.
CN2005800261833A CN101001873B (zh) 2004-08-04 2005-07-18 Fc区变体
IL180885A IL180885A0 (en) 2004-08-04 2007-01-22 Variant fc regions
NO20071192A NO339556B1 (no) 2004-08-04 2007-03-02 Anti-CD20 antistoff og farmasøytisk sammensetning

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US59885504P 2004-08-04 2004-08-04
US60/598,855 2004-08-04
US60295304P 2004-08-19 2004-08-19
US60/602,953 2004-08-19
US60433904P 2004-08-25 2004-08-25
US60/604,339 2004-08-25
US60910104P 2004-09-10 2004-09-10
US60/609,101 2004-09-10
US63844204P 2004-12-23 2004-12-23
US60/638,442 2004-12-23
US64371805P 2005-01-13 2005-01-13
US60/643,718 2005-01-13

Publications (2)

Publication Number Publication Date
WO2006020114A2 WO2006020114A2 (fr) 2006-02-23
WO2006020114A3 true WO2006020114A3 (fr) 2006-04-06

Family

ID=35276048

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/025276 Ceased WO2006020114A2 (fr) 2004-08-04 2005-07-18 Regions fc de variants

Country Status (16)

Country Link
US (1) US7740847B2 (fr)
EP (2) EP2213683B1 (fr)
JP (2) JP5055603B2 (fr)
KR (1) KR100864549B1 (fr)
CN (1) CN101001873B (fr)
AU (1) AU2005274905B2 (fr)
BR (2) BR122018016031B8 (fr)
CA (2) CA2779559A1 (fr)
DK (2) DK1776384T3 (fr)
EA (1) EA012464B1 (fr)
ES (2) ES2426816T3 (fr)
IL (1) IL180885A0 (fr)
MX (1) MX2007001345A (fr)
NO (1) NO339556B1 (fr)
PL (2) PL1776384T3 (fr)
WO (1) WO2006020114A2 (fr)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7557190B2 (en) 2005-07-08 2009-07-07 Xencor, Inc. Optimized proteins that target Ep-CAM
US7655228B2 (en) 1999-04-09 2010-02-02 Kyowa Hakko Kirin Co., Ltd Method of modulating the activity of functional immune molecules to GM2
US7737325B2 (en) 2000-10-06 2010-06-15 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell
US8133982B2 (en) 2004-05-10 2012-03-13 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8647625B2 (en) 2004-07-26 2014-02-11 Biogen Idec Ma Inc. Anti-CD154 antibodies
US8852586B2 (en) 2004-11-12 2014-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8951517B2 (en) 2003-01-09 2015-02-10 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US8969526B2 (en) 2011-03-29 2015-03-03 Roche Glycart Ag Antibody Fc variants
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8993730B2 (en) 2008-04-02 2015-03-31 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
US9096877B2 (en) 2009-10-07 2015-08-04 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US9243069B2 (en) 2008-04-02 2016-01-26 Macrogenics, Inc. HER2/neu-specific antibodies and methods of using the same
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9296816B2 (en) 2005-04-15 2016-03-29 Macrogenics, Inc. Covalent diabodies and uses thereof
US9376495B2 (en) 2011-05-21 2016-06-28 Macrogenics, Inc. Deimmunized serum-binding domains and their use in extending serum half-life
US9441049B2 (en) 2010-03-04 2016-09-13 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
US11851476B2 (en) 2011-10-31 2023-12-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain

Families Citing this family (244)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
AU2002236517A1 (en) * 2000-11-29 2002-06-11 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP2368578A1 (fr) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification et ingénierie d'anticorps avec régions FC de variante et procédés d'utilisation associés
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
ES2366617T3 (es) * 2003-04-21 2011-10-21 Epeius Biotechnologies Corporation Métodos y composiciones para el tratamiento de transtornos.
US20090123428A1 (en) * 2003-04-21 2009-05-14 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US20070178066A1 (en) * 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
WO2006085967A2 (fr) * 2004-07-09 2006-08-17 Xencor, Inc. Anticorps monoclonaux optimises anti-cd20 a variants fc
US7740847B2 (en) 2004-08-04 2010-06-22 Applied Molecular Evolution, Inc. Variant Fc regions
WO2007024249A2 (fr) 2004-11-10 2007-03-01 Macrogenics, Inc. Fonction effectrice obtenue par creation par genie biologique de regions d'anticorps fc
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US20110123440A1 (en) * 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2007005612A2 (fr) * 2005-07-01 2007-01-11 Medimmune, Inc. Approche integree permettant de generer des applications therapeutiques a base de proteine multidomaine
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
CA2618681C (fr) 2005-08-10 2015-10-27 Macrogenics, Inc. Identification et ingenierie d'anticorps presentant des zones de variants fc et procedes d'utilisation de ces anticorps
KR20080073293A (ko) 2005-10-14 2008-08-08 메디뮨 엘엘씨 항체 라이브러리의 세포 디스플레이
WO2007114319A1 (fr) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Procédé de régulation de la cinétique sanguine d'un anticorps
EP4218801A3 (fr) 2006-03-31 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'anticorps pour purifier un anticorps bispécifique
DK2029173T3 (en) 2006-06-26 2016-11-07 Macrogenics Inc FC-RIIB-specific antibodies and methods of use thereof
CA2656224C (fr) 2006-06-26 2018-01-09 Macrogenics, Inc. Association d'anticorps anti-fc.gamma.riib et d'anticorps anti-cd20, et methodes d'utilisation
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
KR101546441B1 (ko) 2006-12-20 2015-08-24 엠엠알글로벌, 인코포레이티드 항체 및 이들의 제조 및 사용 방법
AU2013202392B2 (en) * 2006-12-20 2016-02-25 Mmrglobal, Inc. Antibodies and methods for making and using them
BRPI0809042B1 (pt) 2007-03-22 2021-08-31 Biogen Ma Inc. Proteína de ligação a cd154 isolada, seu uso, e composição
EP2703011A3 (fr) 2007-05-07 2014-03-26 MedImmune, LLC Anticorps anti-ICOS et leur utilisation dans le traitement de l'oncologie, la transplantation et les maladies auto-immunes
EP2626371A1 (fr) 2007-07-31 2013-08-14 MedImmune, LLC Protéines de liaison d'épitope multispécifique et leurs utilisations
SI2187965T1 (sl) 2007-08-17 2020-03-31 Purdue Research Foundation Office Of Technology Commercialization Konjugati vezalca ligand-veznika PSMA in metode za uporabo
SI2202245T1 (sl) 2007-09-26 2016-10-28 Chugai Seiyaku Kabushiki Kaisha Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
WO2009117030A2 (fr) 2007-12-19 2009-09-24 Macrogenics, Inc. Compositions améliorées pour la prévention et le traitement de la variole
AU2008339576B2 (en) 2007-12-21 2014-05-22 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Ralpha)
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
RU2529951C2 (ru) 2007-12-26 2014-10-10 Ксенкор, Инк. ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn
KR20100107501A (ko) 2008-01-18 2010-10-05 메디뮨 엘엘씨 부위 특이적 접합을 위한 시스테인 조작 항체
ES2978400T3 (es) 2008-04-11 2024-09-11 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno capaz de unirse repetidamente a dos o más moléculas de antígeno
US8314213B2 (en) 2008-04-18 2012-11-20 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
BRPI0917204A2 (pt) * 2008-07-21 2015-12-01 Immunomedics Inc variantes estruturais de anticorpos para melhores características terapêuticas
ES2828721T3 (es) * 2008-10-14 2021-05-27 Genentech Inc Variantes de inmunoglobulina y usos de las mismas
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
JP5918129B2 (ja) 2009-06-22 2016-05-18 メディミューン，エルエルシー 部位特異的共役のための操作されたＦｃ領域
WO2011028952A1 (fr) 2009-09-02 2011-03-10 Xencor, Inc. Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes
WO2011091078A2 (fr) 2010-01-19 2011-07-28 Xencor, Inc. Variants d'anticorps possédant une activité complémentaire accrue
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
BR112013002533A2 (pt) 2010-08-02 2021-09-08 Macrogenics, Inc Polipeptídeo de ligação de proteína sérica e diacorpo complexado ao polipeptídeo de ligação de proteína sérica
AU2011288412A1 (en) 2010-08-13 2013-02-21 Medimmune Limited Monomeric polypeptides comprising variant Fc regions and methods of use
WO2012022734A2 (fr) 2010-08-16 2012-02-23 Medimmune Limited Anticorps anti-icam-1 et procédés d'utilisation
WO2012032080A1 (fr) 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Fc humain stabilisé
RU2013115927A (ru) 2010-09-10 2014-10-20 Апексиджен, Инк. АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
KR20140032944A (ko) * 2010-10-20 2014-03-17 모르포테크, 인크. 항폴레이트 수용체 알파 항체 당형태
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
EP4303237A3 (fr) 2010-11-30 2024-03-27 Chugai Seiyaku Kabushiki Kaisha Agent thérapeutique inducteur de cytotoxicité
HUE035281T2 (en) 2011-01-14 2018-05-02 Univ California Therapeutic antibodies against ror-1 protein and methods for use of same
EP2673297A2 (fr) 2011-02-11 2013-12-18 Zyngenia, Inc. Complexes plurispécifiques monovalents et multivalents et leurs utilisations
CN103492565B (zh) 2011-02-25 2021-01-29 中外制药株式会社 FcγRIIb特异性Fc抗体
RU2013144392A (ru) 2011-03-03 2015-04-10 Апексиджен, Инк. Антитела к рецептору il-6 и способы применения
AU2012225246B2 (en) 2011-03-10 2016-01-21 Omeros Corporation Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
DK2697257T3 (en) 2011-04-13 2017-01-30 Bristol Myers Squibb Co FC FUSION PROTEINS INCLUDING UNKNOWN LINKERS OR EVENTS
MX339239B (es) 2011-04-29 2016-05-18 Apexigen Inc Anticuerpos anti-cd40 y metodos de uso.
CA2837169C (fr) 2011-05-24 2021-11-09 Zyngenia, Inc. Complexes multispecifiques contenant un peptide de liaison de l'angiopoietin-2 et utilisations connexes
DK2728002T3 (da) 2011-06-30 2022-04-04 Chugai Pharmaceutical Co Ltd Heterodimeriseret polypeptid
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
WO2013025446A2 (fr) 2011-08-12 2013-02-21 Omeros Corporation Anticorps monoclonaux anti-fzd10 et leurs procédés d'utilisation
WO2013047748A1 (fr) 2011-09-30 2013-04-04 中外製薬株式会社 Molécule se liant à l'antigène favorisant la disparition des antigènes ayant une pluralité d'activités biologiques
AU2012317395B2 (en) 2011-09-30 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule inducing immune response to target antigen
WO2013047752A1 (fr) * 2011-09-30 2013-04-04 中外製薬株式会社 Molécule de liaison aux antigènes pour favoriser la perte d'antigènes
ES2757473T3 (es) 2011-09-30 2020-04-29 Dana Farber Cancer Inst Inc Péptidos terapéuticos que comprenden anticuerpos que se unen a la secuencia A relacionada con el polipéptido del CMH de clase I (MICA)
TW201817745A (zh) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
RU2014122184A (ru) 2011-11-02 2015-12-10 Апексиджен, Инк. Антитела к kdr и способы их применения
ES2749349T3 (es) 2011-11-07 2020-03-19 Medimmune Llc Proteínas de unión multiespecíficas y multivalentes y usos de las mismas
EP2787081A4 (fr) * 2011-11-30 2015-10-07 Chugai Pharmaceutical Co Ltd Support contenant des médicaments dans une cellule pour former un complexe immunitaire
US11147852B2 (en) 2011-12-23 2021-10-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
KR102041412B1 (ko) * 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
WO2013118858A1 (fr) 2012-02-09 2013-08-15 中外製薬株式会社 Région fc modifiée d'un anticorps
DK2818183T3 (da) 2012-02-24 2020-06-15 Chugai Pharmaceutical Co Ltd Antigen-bindende molekyle til at fremme forsvinden af antigen ved hjælp af Fc RIIB
US9751942B2 (en) 2012-03-29 2017-09-05 Chugai Seiyaku Kabushiki Kaisha Anti-LAMP5 antibody and utilization thereof
DK2857420T3 (da) 2012-05-30 2020-11-23 Chugai Pharmaceutical Co Ltd Målvævsspecifikt antigenbindende molekyle
DK2857419T3 (da) 2012-05-30 2021-03-29 Chugai Pharmaceutical Co Ltd Antigen-bindende molekyle til eliminering af aggregerede antigener
SG10201605703TA (en) * 2012-07-06 2016-09-29 Genmab Bv Dimeric protein with triple mutations
ES2758979T3 (es) * 2012-07-06 2020-05-07 Genmab Bv Proteína dimérica con mutaciones triples
US10919953B2 (en) * 2012-08-24 2021-02-16 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific Fc region variant
EP2889376A4 (fr) 2012-08-24 2016-11-02 Chugai Pharmaceutical Co Ltd ANTICORPS Fc SPÉCIFIQUE À FcyRII DE SOURIS
US9676861B2 (en) 2012-10-30 2017-06-13 Apexigen, Inc. Anti-CD40 antibodies and methods of use
CA2886987C (fr) * 2012-11-08 2022-07-12 Eleven Biotherapeutics, Inc. Antagonistes de l'il-6 et leurs utilisations
KR102318999B1 (ko) 2012-11-15 2021-10-29 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
PT2928923T (pt) 2012-12-10 2020-03-27 Biogen Ma Inc Anticorpos antígenos 2 de células dendríticas anti-sangue e os seus usos
EP4119947A1 (fr) 2012-12-21 2023-01-18 Chugai Seiyaku Kabushiki Kaisha Médicament de ciblage gpc3 administré à un patient en réponse à une thérapie médicamenteuse de ciblage gpc3
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
JP6433297B2 (ja) 2012-12-27 2018-12-05 中外製薬株式会社 ヘテロ二量化ポリペプチド
ES2984345T3 (es) * 2013-01-10 2024-10-29 Genmab Bv Variantes de la región FC de IGG1 humana y usos de las mismas
WO2014126871A1 (fr) 2013-02-12 2014-08-21 Bristol-Myers Squibb Company Procédés de repliement de protéine utilisant la filtration tangentielle
ES2751735T3 (es) 2013-02-12 2020-04-01 Bristol Myers Squibb Co Métodos de replegado de proteínas a elevado pH
HUE055845T2 (hu) 2013-03-14 2021-12-28 Macrogenics Inc Aktiváló receptort expresszáló immuneffektor sejtekkel immunreaktív bispecifikus molekulák
WO2014144466A1 (fr) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anticorps anti-alpha ν bêta 6 et leurs utilisations
AU2014228502A1 (en) 2013-03-15 2015-08-20 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
ES2708565T3 (es) 2013-03-15 2019-04-10 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
EA201890895A1 (ru) 2013-03-15 2019-02-28 Зинджения, Инк. Мультивалентные и моновалентные мультиспецифические комплексы и их применение
WO2014151680A1 (fr) 2013-03-15 2014-09-25 Biogen Idec Ma Inc. Traitement et prévention d'une lésion rénale aiguë à l'aide d'anticorps anti- αvβ5
KR20210130260A (ko) 2013-04-02 2021-10-29 추가이 세이야쿠 가부시키가이샤 Ｆｃ영역 개변체
BR112015032414A2 (pt) 2013-06-24 2017-11-07 Chugai Pharmaceutical Co Ltd agente terapêutico compreendendo anticorpo antiepirregulina humanizado como ingrediente ativo para carcinoma de pulmão de célula não pequena excluindo adenocarcinoma
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP2839842A1 (fr) 2013-08-23 2015-02-25 MacroGenics, Inc. Bianticorps monovalents bi-spécifiques capables de se lier aux CD123 et CD3 et leurs utilisations
EP2840091A1 (fr) 2013-08-23 2015-02-25 MacroGenics, Inc. Diabody se liant specifiquement a l'antigene gpA33 et CD3 et procedes d'utilisation
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
ES2837392T3 (es) 2013-10-02 2021-06-30 Medimmune Llc Anticuerpos anti-influenza A neutralizantes y usos de los mismos
WO2015057939A1 (fr) 2013-10-18 2015-04-23 Biogen Idec Ma Inc. Anticorps anti-s1p4 et leurs utilisations
WO2015055318A1 (fr) 2013-10-18 2015-04-23 Deutsches Krebsforschungszentrum Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate
EP3777898B1 (fr) 2013-11-14 2025-01-01 Endocyte, Inc. Composés pour la tomographie par émission de positrons
US10961530B2 (en) 2013-12-04 2021-03-30 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
BR112016012358A2 (pt) 2013-12-06 2017-09-26 Dana Farber Cancer Inst Inc peptídios terapêuticos
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
CA3124243A1 (fr) 2014-03-14 2015-09-17 Dana-Farber Cancer Institute, Inc. Compositions vaccinales et methodes pour retablir la fonction de la voie nkg2d contre les cancers
CN118440206A (zh) 2014-04-07 2024-08-06 中外制药株式会社 免疫活化抗原结合分子
SG11201609014TA (en) 2014-05-08 2016-12-29 Chugai Pharmaceutical Co Ltd Gpc3 -targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
CN106459954A (zh) 2014-05-13 2017-02-22 中外制药株式会社 用于具有免疫抑制功能的细胞的t细胞重定向的抗原结合分子
CN106413750B (zh) 2014-05-16 2022-04-29 免疫医疗有限责任公司 具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子
RS59643B1 (sr) 2014-06-06 2020-01-31 Bristol Myers Squibb Co Antitela na glukokortikoidom indukovani receptor faktora nekroze tumora (gitr) i njihova primena
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
BR112017006515A8 (pt) 2014-09-29 2018-02-27 Univ Duke moléculas biespecíficas, composições, método para tratar ou prevenir infecção por hiv-1 em um indivíduo com essa necessidade, e vetor
DK4268843T3 (da) 2014-11-07 2025-11-10 F Hoffmann La Roche Ltd Forbedrede IL-6-antistoffer
SG10201913004UA (en) 2014-11-21 2020-03-30 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
SMT202000579T1 (it) 2014-11-21 2020-11-10 Bristol Myers Squibb Co Anticorpi comprendenti regioni costanti pesanti modificate
EP4600372A3 (fr) 2014-12-19 2025-11-19 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-myostatine, polypeptides contenant des régions fc variantes, et procédés d'utilisation
EP3233921B1 (fr) 2014-12-19 2021-09-29 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-c5 et leurs procédés d'utilisation
JP6180663B2 (ja) 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
TW202446796A (zh) 2015-02-05 2024-12-01 日商中外製藥股份有限公司 包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
LT3280432T (lt) 2015-04-06 2021-06-25 Subdomain, Llc De novo surišantis domenas, kurio sudėtyje yra polipeptidai, ir jo naudojimas
TN2019000101A1 (en) 2015-05-29 2020-07-15 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof.
WO2017008169A1 (fr) 2015-07-15 2017-01-19 Zymeworks Inc. Constructions bispécifiques de liaison à un antigène conjuguées à un médicament
PH12018500386B1 (en) 2015-09-18 2024-01-05 Chugai Pharmaceutical Co Ltd Il-8-binding antibodies and uses thereof
EP3378488A4 (fr) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Procédé pour renforcer la réponse immunitaire humorale
WO2017086367A1 (fr) 2015-11-18 2017-05-26 中外製薬株式会社 Polythérapie utilisant une molécule de liaison à l'antigène à rôle de redirection des cellules t, ciblant des cellules immunosupressives
SG11201803817PA (en) 2015-11-19 2018-06-28 Bristol Myers Squibb Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
CN108884158A (zh) * 2015-12-01 2018-11-23 根马布有限公司 抗死亡受体抗体及其使用方法
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
MX2018007781A (es) 2015-12-28 2018-09-05 Chugai Pharmaceutical Co Ltd Metodo para promover la eficiencia de purificacion del polipeptido que contiene la region de fragmento cristalizable (fc).
MX2018010032A (es) 2016-02-23 2019-03-11 Sesen Bio Inc Formulaciones de antagonista de il-6 y sus usos.
AU2017228470A1 (en) 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
TW202214700A (zh) 2016-03-14 2022-04-16 日商中外製藥股份有限公司 用於癌之治療的細胞傷害誘導治療劑
JP6430025B2 (ja) 2016-03-15 2018-11-28 中外製薬株式会社 Ｐｄ−１系結合アンタゴニストおよび抗ｇｐｃ３抗体を使用して癌を治療する方法
US20190077870A1 (en) 2016-03-16 2019-03-14 Merrimack Pharmaceuticals, Inc. Engineered trail for cancer therapy
UA127341C2 (uk) 2016-04-15 2023-07-26 Мекроудженікс, Інк. Виділена b7-н3-зв'язувальна молекула
EA039084B1 (ru) 2016-05-09 2021-12-01 Бристол-Майерс Сквибб Компани Антитела к tl1a и их применения
PE20190418A1 (es) 2016-07-14 2019-03-19 Bristol Myers Squibb Co Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos
US20190330318A1 (en) 2016-07-25 2019-10-31 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
SG11201900616UA (en) 2016-08-02 2019-02-27 Visterra Inc Engineered polypeptides and uses thereof
EP3494991A4 (fr) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Composition pour la prophylaxie ou le traitement de maladies liées à il-8
EP3497120A1 (fr) 2016-08-12 2019-06-19 Janssen Biotech, Inc. Conception d'anticorps modifiés et d'autres molécules contenant un domaine fc présentant des fonctions d'agonisme et d'effecteur améliorées
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
GB201619652D0 (en) 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel polypeptides
MX2019005772A (es) 2016-11-23 2019-10-02 Bioverativ Therapeutics Inc Anticuerpos mono y biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x.
WO2018139623A1 (fr) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-sclérostine et procédés d'utilisation
CA3051839A1 (fr) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Anticorps anti-alpha-synucleine et leurs utilisations
AU2018227807B2 (en) 2017-02-28 2024-10-10 Seagen Inc. Cysteine mutated antibodies for conjugation
SG11201907867TA (en) 2017-02-28 2019-09-27 Bristol Myers Squibb Co Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
CN110709417B (zh) 2017-04-07 2023-10-31 美天施生物科技有限责任两合公司 具有突变人IgG4的多肽
JP7679175B2 (ja) 2017-04-20 2025-05-19 エータイアー ファーマ， インコーポレイテッド 肺の炎症を治療するための組成物および方法
WO2018213097A1 (fr) 2017-05-15 2018-11-22 University Of Rochester Anticorps monoclonal anti-virus de la grippe à large neutralisation et utilisations associées
KR20240149979A (ko) 2017-05-25 2024-10-15 브리스톨-마이어스 스큅 컴퍼니 변형된 중쇄 불변 영역을 포함하는 항체
EP3634486A4 (fr) * 2017-06-05 2021-03-31 Janssen Biotech, Inc. Anticorps multispécifiques modifiés et autres protéines multimères avec des mutations de région ch2-ch3 asymétriques
DK3456736T3 (da) * 2017-09-19 2021-05-03 Tillotts Pharma Ag Antistofvarianter
JP7382922B2 (ja) 2017-09-20 2023-11-17 中外製薬株式会社 Ｐｄ－１系結合アンタゴニストおよびｇｐｃ３標的化剤を使用する併用療法のための投与レジメン
EP3694552A1 (fr) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anticorps anti-lap et leurs utilisations
JP7731196B2 (ja) 2017-11-14 2025-08-29 中外製薬株式会社 抗Ｃ１ｓ抗体および使用方法
RS67119B1 (sr) 2017-11-14 2025-09-30 Arcellx Inc Polipeptidi koji obuhvataju d domen i njihove upotrebe
AU2018368431B2 (en) 2017-11-14 2024-03-21 Arcellx, Inc. Multifunctional immune cell therapies
US12006368B2 (en) 2017-12-19 2024-06-11 Surrozen Operating, Inc. Anti-frizzled antibodies and methods of use
CN118271444A (zh) 2017-12-19 2024-07-02 瑟罗泽恩奥普瑞汀公司 Wnt替代分子和其用途
CA3085785A1 (fr) 2017-12-19 2019-06-27 Surrozen, Inc. Anticorps anti-lrp5/6 et leurs procedes d'utilisation
US12139533B2 (en) 2017-12-20 2024-11-12 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-CD200 antibodies
WO2019126536A1 (fr) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Anticorps humanisés anti-cd200 et leurs utilisations
WO2019140229A1 (fr) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Anticorps dirigés contre tim3 et leurs utilisations
JP2021510740A (ja) * 2018-01-24 2021-04-30 ゲンマブ ビー．ブイ． ポリペプチド変種およびそれらの用途
JP2018138022A (ja) * 2018-02-23 2018-09-06 ゲンマブ ビー．ブイ． ヒトＩｇＧ１ Ｆｃ領域変異体およびその使用
TWI827585B (zh) 2018-03-15 2024-01-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
JP7510879B2 (ja) 2018-03-21 2024-07-04 ファイヴ プライム セラピューティクス インク 酸性ｐＨでＶＩＳＴＡに結合する抗体
KR102761890B1 (ko) 2018-03-23 2025-02-06 브리스톨-마이어스 스큅 컴퍼니 Mica 및/또는 micb에 대한 항체 및 그의 용도
MA52190A (fr) 2018-04-02 2021-02-17 Bristol Myers Squibb Co Anticorps anti-trem-1 et utilisations associées
SG11202010217YA (en) 2018-04-17 2020-11-27 Endocyte Inc Methods of treating cancer
CA3096703A1 (fr) 2018-05-03 2019-11-07 University Of Rochester Anticorps monoclonaux de la neuraminidase anti-grippe et leurs utilisations
EP3805400A4 (fr) * 2018-06-04 2022-06-29 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à un antigène présentant une demi-vie modifiée dans le cytoplasme
CA3104526A1 (fr) 2018-07-05 2020-01-09 Surrozen, Inc. Molecules de substitution de wnt multispecifiques et leurs utilisations
AU2019302454A1 (en) 2018-07-09 2021-02-25 Bristol-Myers Squibb Company Antibodies binding to ILT4
PE20210687A1 (es) 2018-07-11 2021-04-08 Bristol Myers Squibb Co Anticuerpos de union a vista a ph acido
BR112021002037A2 (pt) 2018-08-10 2021-05-04 Chugai Seiyaku Kabushiki Kaisha molécula de ligação de antígeno anti-cd137 e uso da mesma
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
CN113348177A (zh) 2018-11-28 2021-09-03 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
US12351622B2 (en) 2018-12-05 2025-07-08 Bica Therapeutics Inc. Modified product of Fc domain of antibody
US12428484B2 (en) 2018-12-06 2025-09-30 Alexion Pharmaceuticals, Inc. Anti-ALK2 antibodies and uses thereof
PE20212305A1 (es) 2019-01-22 2021-12-10 Bristol Myers Squibb Co Anticuerpos contra subunidad alfa il-7r y usos de estos
EP3943108A4 (fr) 2019-03-19 2023-01-04 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à l'antigène contenant un domaine de liaison à l'antigène dont l'activité de liaison à l'antigène est modifiée en fonction de la mta, et banque pour obtenir ledit domaine de liaison à l'antigène
AU2020272766A1 (en) 2019-04-08 2021-11-18 Biogen Ma Inc. Anti-integrin antibodies and uses thereof
EP3955960B1 (fr) 2019-04-18 2025-01-15 Bristol-Myers Squibb Company Variants d'ipilimumab à spécificité améliorée pour la liaison à faible ph
KR20220016865A9 (ko) 2019-05-15 2022-02-21 추가이 세이야쿠 가부시키가이샤 항원 결합 분자, 약학 조성물, 및 방법
CN120097930A (zh) 2019-05-20 2025-06-06 因多塞特股份有限公司 制备psma缀合物的方法
US20220372139A1 (en) 2019-07-15 2022-11-24 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
EP3999541A1 (fr) 2019-07-15 2022-05-25 Bristol-Myers Squibb Company Anticorps dirigés contre trem-1 humain et ses utilisations
AU2020350689A1 (en) 2019-09-19 2022-03-31 Bristol-Myers Squibb Company Antibodies binding to VISTA at acidic pH
WO2021201236A1 (fr) 2020-04-01 2021-10-07 協和キリン株式会社 Composition d'anticorps
CA3170570A1 (fr) 2020-04-01 2021-10-07 James J. KOBIE Anticorps monoclonaux contre l'hemagglutinine (ha) et la neuraminidase (na) des virus de la grippe h3n2
WO2021207449A1 (fr) 2020-04-09 2021-10-14 Merck Sharp & Dohme Corp. Anticorps anti-lap à maturation d'affinité et leurs utilisations
EP3921034A2 (fr) 2020-04-28 2021-12-15 The Rockefeller University Anticorps anti-sras-cov-2 neutralisants et leurs procédés d'utilisation
WO2021231732A1 (fr) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Anticorps anti-garp
JP7048665B2 (ja) * 2020-05-22 2022-04-05 ゲンマブ ビー．ブイ． ヒトＩｇＧ１ Ｆｃ領域変異体およびその使用
WO2021251438A1 (fr) 2020-06-10 2021-12-16 株式会社バイカ・セラピュティクス Protéine de fusion contenant un polypeptide d'érythropoïétine
CN116096741B (zh) 2020-07-10 2024-10-18 因外泰克斯公司 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法
AR123997A1 (es) 2020-11-04 2023-02-01 Univ Rockefeller ANTICUERPOS NEUTRALIZANTES CONTRA EL SARS-CoV-2
US20240059763A1 (en) 2020-12-18 2024-02-22 Zhuhai Trinomab Pharmaceutical Co., Ltd. Respiratory syncytial virus-specific binding molecule
WO2022136569A1 (fr) 2020-12-23 2022-06-30 Cantargia Ab Anticorps anti-il1rap
JP2024505636A (ja) 2021-01-15 2024-02-07 ザ ロックフェラー ユニバーシティー 抗ｓａｒｓ－ｃｏｖ－２中和抗体
AU2022242842A1 (en) 2021-03-26 2023-10-05 Arcellx, Inc. Multifunctional immune cell therapies
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
US20240218057A1 (en) 2021-05-06 2024-07-04 The Rockefeller University Neutralizing anti- sars-cov-2 antibodies and methods of use thereof
WO2023147399A1 (fr) 2022-01-27 2023-08-03 The Rockefeller University Anticorps anti-sars-cov-2 largement neutralisants ciblant le domaine n-terminal de la protéine de spicule et leurs procédés d'utilisation
WO2023191766A1 (fr) * 2022-03-28 2023-10-05 Intervexion Therapeutics, Llc Anticorps ayant une affinité de fcrn modifiée
AR129991A1 (es) 2022-07-22 2024-10-23 Bristol Myers Squibb Co Anticuerpos que se unen a la pad4 humana y usos de los mismos
WO2024107749A1 (fr) 2022-11-16 2024-05-23 Attralus, Inc. Protéines de fusion se liant à l'amyloïde et au récepteur de la transferrine et leurs utilisations
TW202500583A (zh) * 2023-03-17 2025-01-01 美商美國禮來大藥廠 Pd-1促效劑抗體及以pd-1促效劑抗體治療發炎或自體免疫皮膚疾病之方法
WO2024200573A1 (fr) 2023-03-27 2024-10-03 LAVA Therapeutics N.V. Agents de liaison à la nectine-4 et méthodes d'utilisation
AU2024270136A1 (en) 2023-05-05 2025-11-20 Otsuka Pharmaceutical Co., Ltd. Anti-il1rap antibodies
WO2025012118A2 (fr) 2023-07-07 2025-01-16 LAVA Therapeutics N.V. Agents de liaison à 5t4 et méthodes d'utilisation
WO2025024265A1 (fr) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Procédés d'évaluation de la citrullination et de l'activité de modulateurs de pad4
WO2025026282A1 (fr) * 2023-07-29 2025-02-06 Shanghai Kaijin Biotechnology, Ltd Anticorps multispécifiques de type e modifiés
WO2025072888A2 (fr) 2023-09-28 2025-04-03 Novavax, Inc. Anticorps de spicule (s) anti-sars-cov-2 et leur utilisation dans le traitement du covid-19
WO2025085489A1 (fr) 2023-10-17 2025-04-24 Bristol-Myers Squibb Company Composés de dégradation de gspt1, anticorps anti-cd33 et conjugués anticorps-médicament, et leurs utilisations
WO2025088546A1 (fr) * 2023-10-25 2025-05-01 Ablynx N.V. Variants de domaine fc avec liaison de récepteur fc améliorée
WO2025155877A2 (fr) 2024-01-18 2025-07-24 The Regents Of The University Of California Anticorps se liant à la pad4 humaine et leurs utilisations
WO2025174974A1 (fr) 2024-02-14 2025-08-21 Bristol-Myers Squibb Company Anticorps anti-cd33 et leurs utilisations
WO2025184208A1 (fr) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anticorps anti-ceacam5 et leurs utilisations
US20250269052A1 (en) 2024-02-27 2025-08-28 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates
EP4653010A1 (fr) 2024-05-14 2025-11-26 35Pharma Inc. Variants du récepteur de l'activine de type iib et leurs utilisations

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (fr) * 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
WO2000040272A2 (fr) * 1999-01-04 2000-07-13 Ml Laboratories Plc Therapie genique 2
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
WO2004063351A2 (fr) * 2003-01-09 2004-07-29 Macrogenics, Inc. Identification et elaboration d'anticorps avec des regions du variant fc et procedes d'utilisation associes
WO2004099249A2 (fr) * 2003-05-02 2004-11-18 Xencor, Inc. Variants fc optimises et leurs procedes de generation
WO2005056606A2 (fr) * 2003-12-03 2005-06-23 Xencor, Inc Proteines optimisees qui ciblent le recepteur du facteur de croissance epidermique
WO2005070963A1 (fr) * 2004-01-12 2005-08-04 Applied Molecular Evolution, Inc Variants de la region fc

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5985599A (en) 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
IL84285A (en) 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4861579A (en) 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
GB8916400D0 (en) 1989-07-18 1989-09-06 Dynal As Modified igg3
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
EP0556285A4 (en) 1990-11-05 1993-10-27 Bristol-Myers Squibb Company Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
GB9105245D0 (en) 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
CA2118508A1 (fr) 1992-04-24 1993-11-11 Elizabeth S. Ward Production par recombinaison genetique de domaines semblables aux immunoglobulines dans les cellules procaryotes
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5550362A (en) 1992-11-20 1996-08-27 Intermec Corporation Method and apparatus for calibrating a bar code scanner
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5417972A (en) 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
GB9316989D0 (en) 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
CA2195557C (fr) 1994-08-12 2006-10-17 Shui-On Leung Immunoconjugues et anticorps de type humain specifiques contre des lymphomes malins a cellules b et des cellules leucemiques
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
EP0918872B1 (fr) 1996-08-02 2008-02-20 Bristol-Myers Squibb Company Procede servant a inhiber la toxicite provoquee par les immunoglobulines provenant de l'utilisation d'immunoglobulines en therapie et en diagnostic in vivo
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
DE19721700C1 (de) 1997-05-23 1998-11-19 Deutsches Krebsforsch Mutierter OKT3-Antikörper
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
DK0999853T3 (da) 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
WO1998058964A1 (fr) 1997-06-24 1998-12-30 Genentech, Inc. Procedes et compositions concernant des glycoproteines galactosylees
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
BR9913645A (pt) 1998-08-11 2001-09-25 Idec Pharma Corp Terapias combinadas para linfomas de células b compreendendo a administração de anticorpo anti-cd20
WO2000009560A2 (fr) 1998-08-17 2000-02-24 Abgenix, Inc. Production de molecules modifiees avec demi-vie serique prolongee
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
BR9915149A (pt) 1998-11-09 2001-08-07 Idec Pharma Corp Tratamento com anticorpo anti-cd20 quimérico de pacientes recebendo transplantes de bmt ou de pbsc
EP1616572B1 (fr) 1998-11-09 2010-09-01 Biogen Idec Inc. Anticorps chimère anti-CD20, rituxan, pour l'utilisation dans le traitement de la leucémie chronique lymphatique
DK1135498T3 (da) 1998-11-18 2008-05-26 Genentech Inc Antistofvarianter med höjere bindingsaffinitet end forældreantistoffer
NZ539776A (en) 1999-01-15 2006-12-22 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
MXPA01011279A (es) 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
HK1046635B (en) 1999-06-09 2009-10-09 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
ITMI991299A1 (it) 1999-06-11 2000-12-11 Consiglio Nazionale Ricerche Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
IL147547A0 (en) 1999-07-12 2002-08-14 Genentech Inc Blocking immune response to a foreign antigen using an antagonist which binds to cd20
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
CA2378646A1 (fr) 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Traitement pour patients atteint d'un lymphome different de la maladie de hodgkins et qui touche la moelle osseuse, avec des anticorps anti-cd20
AU6929100A (en) 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
US6656467B2 (en) 2000-01-27 2003-12-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
CN1406249B (zh) 2000-02-11 2010-06-16 默克专利股份有限公司 增加基于抗体的融合蛋白的循环半衰期
MXPA02009626A (es) 2000-03-31 2003-05-14 Idec Pharma Corp Uso combinado de anticuerpos anti-citocina o antagonistas y anti-cd20 para el tratamiento de linfoma de celulas b.
AU5345901A (en) 2000-04-13 2001-10-30 Univ Rockefeller Enhancement of antibody-mediated immune responses
AU5914201A (en) 2000-04-25 2001-11-07 Idec Pharma Corp Intrathecal administration of rituximab for treatment of central nervous system lymphomas
EP2052742A1 (fr) 2000-06-20 2009-04-29 Biogen Idec Inc. Traitement de maladies liées aux lymphocytes B telles des tumeurs et des maladies auto-immunes utilisant une combinaison d'anticorps anti-CD20 froid et d'anticorps anti-CD22 radiomarqué
US20020128448A1 (en) 2000-10-20 2002-09-12 Idec Pharmaceuticals Corporation Variant IgG3 Rituxan and therapeutic use thereof
WO2002060919A2 (fr) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules a demi-vies longues, compositions et utilisations de celles-ci
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
NZ545176A (en) 2001-01-29 2008-05-30 Biogen Idec Inc Modified antibodies reactive with CD20 and methods of use
EP1383800A4 (fr) 2001-04-02 2004-09-22 Idec Pharma Corp Anticorps recombinants co-exprimes avec gntiii
JP4679035B2 (ja) 2001-04-02 2011-04-27 ジェネンテック， インコーポレイテッド 併用療法
WO2003061694A1 (fr) 2001-05-10 2003-07-31 Seattle Genetics, Inc. Immunosuppression de la reponse immune humorale par des anticorps anti-cd20
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
EP1519959B1 (fr) 2002-02-14 2014-04-02 Immunomedics, Inc. Anticorps anti-cd20 et proteines hybrides desdits anticorps, et methodes d'utilisation
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EP1534335B9 (fr) 2002-08-14 2016-01-13 Macrogenics, Inc. Anticorps specifiques du recepteur fcgammariib et procedes d'utilisation de ces anticorps
KR100960560B1 (ko) 2002-09-27 2010-06-03 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체 및 그의 제조 방법
SI1558648T1 (sl) 2002-10-17 2012-05-31 Genmab As Človeška monoklonalna protitelesa proti CD
HU227217B1 (en) 2002-12-16 2010-11-29 Genentech Inc Immunoglobulin variants and uses thereof
JP2006522811A (ja) 2003-04-09 2006-10-05 ジェネンテック・インコーポレーテッド ＴＮＦαインヒビターに対して不十分な反応を示す患者の自己免疫疾患治療法
CA2897608C (fr) 2003-05-09 2018-07-31 Duke University Anticorps specifiques de cd20 et leurs methodes d'utilisation
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
KR101364902B1 (ko) 2003-11-05 2014-02-21 로슈 글리카트 아게 증가된 ｆｃ 수용체 결합 친화성 및 효과기 기능을 가진 ｃｄ20 항체
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
WO2006085967A2 (fr) 2004-07-09 2006-08-17 Xencor, Inc. Anticorps monoclonaux optimises anti-cd20 a variants fc
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
US7740847B2 (en) 2004-08-04 2010-06-22 Applied Molecular Evolution, Inc. Variant Fc regions
GT200500283A (es) 2004-10-08 2006-05-08 Inmunoterapia de desordenes autoinmunes
EP2314618A3 (fr) 2004-11-12 2011-10-19 Xencor Inc. Variants de Fc avec une liaison altérée à FcRn
FR2879204B1 (fr) 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
DOP2006000013A (es) 2005-01-13 2006-07-15 Genentech Inc Dosis de anticuerpos en el tratamiento de enfermedades asociadas a las celulas b
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
WO2006105338A2 (fr) 2005-03-31 2006-10-05 Xencor, Inc. Variants fc presentant des proprietes optimisees

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (fr) * 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
WO2000040272A2 (fr) * 1999-01-04 2000-07-13 Ml Laboratories Plc Therapie genique 2
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
WO2004063351A2 (fr) * 2003-01-09 2004-07-29 Macrogenics, Inc. Identification et elaboration d'anticorps avec des regions du variant fc et procedes d'utilisation associes
WO2004099249A2 (fr) * 2003-05-02 2004-11-18 Xencor, Inc. Variants fc optimises et leurs procedes de generation
WO2005056606A2 (fr) * 2003-12-03 2005-06-23 Xencor, Inc Proteines optimisees qui ciblent le recepteur du facteur de croissance epidermique
WO2005070963A1 (fr) * 2004-01-12 2005-08-04 Applied Molecular Evolution, Inc Variants de la region fc

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
IDUSOGIE ESOHE E ET AL: "Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 164, 2000, pages 4178 - 4184, XP002965858, ISSN: 0022-1767 *
SARMAY G ET AL: "MAPPING AND COMPARISON OF THE INTERACTION SITES ON THE FC REGION OF IGG RESPONSIBLE FOR TRIGGERING ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) THROUGH DIFFERENT TYPES OF HUMAN FCY RECEPTOR", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 29, no. 5, 1992, pages 633 - 639, XP000915240, ISSN: 0161-5890 *
SHIELDS R L ET AL: "High resolution mapping of the binding site on human IgG1 for FcgammaRI, FcgammaRII, FcgammaRIII, and FcRn and design of IgG1 variants with improved binding to the FcgammaR", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 276, no. 9, 2 March 2001 (2001-03-02), pages 6591 - 6604, XP002271092, ISSN: 0021-9258 *
TAN L K ET AL: "INFLUENCE OF THE HINGE REGION ON COMPLEMENT ACTIVATION, C1Q BINDING, AND SEGMENTAL FLEXIBILITY IN CHIMERIC HUMAN IMMUNOGLOBULINS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 87, no. 1, January 1990 (1990-01-01), pages 162 - 166, XP002050454, ISSN: 0027-8424 *

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8679491B2 (en) 1999-04-09 2014-03-25 Kyowa Hakko Kirin Co., Ltd. Method of modulating the activity of functional immune molecules
US7655228B2 (en) 1999-04-09 2010-02-02 Kyowa Hakko Kirin Co., Ltd Method of modulating the activity of functional immune molecules to GM2
US7708997B2 (en) 1999-04-09 2010-05-04 Kyowa Hakko Kirin Co., Ltd Method of modulating the activity of functional immune molecules
US8367407B2 (en) 2000-10-06 2013-02-05 Kyowa Hakko Kirin Co., Ltd. Cells with altered fucosylation and producing antibodies therefrom
US7737325B2 (en) 2000-10-06 2010-06-15 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell
US7846725B2 (en) 2000-10-06 2010-12-07 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell in which enzyme expression is inhibited by RNAi
US8039595B2 (en) 2000-10-06 2011-10-18 Kyowa Hakko Kirin Co., Ltd. Glycoengineered, recombinant antibody to CCR-4 with reduced fucosylation
US8067232B2 (en) 2000-10-06 2011-11-29 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell with inactivated A-1,6-fusocyltransferase
US9409982B2 (en) 2000-10-06 2016-08-09 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell
US8329443B2 (en) 2000-10-06 2012-12-11 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell
US7741442B2 (en) 2000-10-06 2010-06-22 Kyowa Hakko Kirin Co., Ltd Antibody composition exhibiting increased cellular cytotoxicity due to glycosylation
US8895266B2 (en) 2000-10-06 2014-11-25 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8951517B2 (en) 2003-01-09 2015-02-10 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US8133982B2 (en) 2004-05-10 2012-03-13 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8647625B2 (en) 2004-07-26 2014-02-11 Biogen Idec Ma Inc. Anti-CD154 antibodies
US8852586B2 (en) 2004-11-12 2014-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8883973B2 (en) 2004-11-12 2014-11-11 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9296816B2 (en) 2005-04-15 2016-03-29 Macrogenics, Inc. Covalent diabodies and uses thereof
US7557190B2 (en) 2005-07-08 2009-07-07 Xencor, Inc. Optimized proteins that target Ep-CAM
US8993730B2 (en) 2008-04-02 2015-03-31 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
US9469692B2 (en) 2008-04-02 2016-10-18 Macrogenics, Inc. HER2/neu-specific antibodies and methods of using same
US9243069B2 (en) 2008-04-02 2016-01-26 Macrogenics, Inc. HER2/neu-specific antibodies and methods of using the same
US9096877B2 (en) 2009-10-07 2015-08-04 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
US9441049B2 (en) 2010-03-04 2016-09-13 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
US8969526B2 (en) 2011-03-29 2015-03-03 Roche Glycart Ag Antibody Fc variants
US9376495B2 (en) 2011-05-21 2016-06-28 Macrogenics, Inc. Deimmunized serum-binding domains and their use in extending serum half-life
US11851476B2 (en) 2011-10-31 2023-12-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
US10683345B2 (en) 2012-07-13 2020-06-16 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA

Also Published As

Publication number Publication date
EP1776384A2 (fr) 2007-04-25
DK2213683T3 (da) 2013-09-02
JP5055603B2 (ja) 2012-10-24
BRPI0514068A (pt) 2008-05-27
CN101001873B (zh) 2013-03-13
EP2213683A1 (fr) 2010-08-04
BR122018016031B8 (pt) 2021-07-27
KR100864549B1 (ko) 2008-10-20
BR122018016031B1 (pt) 2019-10-22
AU2005274905A1 (en) 2006-02-23
CA2573192C (fr) 2013-09-10
BRPI0514068B1 (pt) 2018-11-27
EP2213683B1 (fr) 2013-06-05
US7740847B2 (en) 2010-06-22
AU2005274905B2 (en) 2010-12-23
IL180885A0 (en) 2007-07-04
EP1776384B1 (fr) 2013-06-05
PL2213683T3 (pl) 2013-10-31
CN101001873A (zh) 2007-07-18
CA2779559A1 (fr) 2006-02-23
JP2008511292A (ja) 2008-04-17
KR20070038541A (ko) 2007-04-10
JP5600697B2 (ja) 2014-10-01
CA2573192A1 (fr) 2006-02-23
JP2012136541A (ja) 2012-07-19
BRPI0514068B8 (pt) 2021-05-25
DK1776384T3 (da) 2013-09-02
MX2007001345A (es) 2008-03-11
NO20071192L (no) 2007-03-05
ES2426816T3 (es) 2013-10-25
EA012464B1 (ru) 2009-10-30
ES2426817T3 (es) 2013-10-25
WO2006020114A2 (fr) 2006-02-23
EA200700210A1 (ru) 2007-08-31
NO339556B1 (no) 2017-01-02
US20070224188A1 (en) 2007-09-27
PL1776384T3 (pl) 2013-10-31

Similar Documents

Publication Publication Date Title
WO2006020114A3 (fr) Regions fc de variants
WO2004078778A3 (fr) Peptides presentant une fixation specifique avec le recepteur de hgf (cmet) et ses utilisations
NO20071419L (no) Polypeptidvarianter med endret effektorfunksjon
WO2004081026A3 (fr) Polypeptides
WO2004080148A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2003012105A3 (fr) Isoforme de facteur de croissance
UA86605C2 (ru) Антитело, которое содержит вариант исходного человеческого fс-участка
WO2005063816A3 (fr) Fragments d'anticorps univalents utiles en tant qu'agents therapeutiques
WO2003054152A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2003026691A3 (fr) Procede
WO2006104989A3 (fr) Anticorps a regions fc modifiees et utilisations
WO2006066024A8 (fr) Motifs de famille de polypeptides pancreatiques, polypeptides et leurs methodes
WO2003011115A3 (fr) Agents de contraste multimères ciblés à base de peptides
PL1789434T3 (pl) Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
WO2005047459A3 (fr) Acides nucleiques du sars, proteines, anticorps et utilisations associees
WO2004087874A3 (fr) Acides nucleiques et polypeptides
WO2003074546A8 (fr) Peptide de liaison a la streptavidine
JP2007510403A5 (fr)
ATE537186T1 (de) P53-bindendes polypeptid
WO2005049806A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2007019865A3 (fr) Traitement au moyen de peptides de liaison cd4 et par rayonnements
WO2003089451A3 (fr) Anticorps specifiques du polypeptide de mucine
WO2006040574A3 (fr) Proteine lipocaline
WO2003091383A3 (fr) Epitopes t de l'antigene epha2.
WO2004020452A3 (fr) Procede de repliement

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005773014

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2573192

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005274905

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 234/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 180885

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 11572634

Country of ref document: US

Ref document number: 2007224188

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 200700210

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2005274905

Country of ref document: AU

Date of ref document: 20050718

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/001345

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 2005274905

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580026183.3

Country of ref document: CN

Ref document number: 1020077002748

Country of ref document: KR

Ref document number: 2007524825

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 1020077002748

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005773014

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11572634

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0514068

Country of ref document: BR